Eton Pharmaceuticals to Participate at Leerink Partners Global Healthcare Conference on Wednesday, March 11th

Rhea-AI Summary

Eton Pharmaceuticals (Nasdaq: ETON) announced its executive leadership will hold one-on-one meetings at the Leerink Partners Global Healthcare Conference on Wednesday, March 11, 2026 in Miami, Florida. Investors and institutional representatives can schedule 1x1 meetings through their Leerink Partners institutional sales representative.

Key Figures

Share price: $18.22 1-day move: 5.87% Today’s volume: 254,932 shares +5 more

8 metrics

Share price $18.22 Pre-news current price for ETON

1-day move 5.87% Price change over prior 24 hours

Today’s volume 254,932 shares Compared with 20-day average of 225,221

52-week range $11.0867 – $23.00 Low–high range before this news

200-day MA $16.80 Long-term moving average level

Q3 2025 product sales $22.5M Reported in Q3 2025 earnings release

Q3 2025 cash $37.1M Cash balance at end of Q3 2025

Q3 2025 Adjusted EBITDA $2.9M From Q3 2025 earnings release

Market Reality Check

Price: $18.22 Vol: Volume 254,932 is 13% abo...

normal vol

$18.22 Last Close

Volume Volume 254,932 is 13% above the 20-day average of 225,221. normal

Technical Price at 18.22 is trading above the 200-day MA of 16.8, and about 20.78% below the 23.00 52-week high.

Peers on Argus

ETON was up 5.87% while momentum data showed peer KMDA down 1.96%; broader peer ...

1 Down

ETON was up 5.87% while momentum data showed peer KMDA down 1.96%; broader peer list had mixed moves, suggesting a stock-specific rather than sector-wide move.

Historical Context

5 past events · Latest: Feb 02 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 02	Product licensing	Positive	+1.1%	Licensed U.S. rights to ultra-rare disease product under FDA review.
Nov 24	Conference appearance	Neutral	+2.7%	Announced fireside chat at Piper Sandler healthcare conference.
Nov 12	Conference meetings	Neutral	-3.3%	Planned 1x1 meetings at Craig-Hallum Alpha Select Conference.
Nov 06	Earnings release	Positive	-0.6%	Reported strong Q3 2025 sales growth and pipeline milestones.
Oct 23	Earnings preview	Neutral	-0.4%	Scheduled Q3 2025 results call and webcast details.

Pattern Detected

Recent ETON news, including conferences and licensing, often led to modest price moves, with a mix of aligned and divergent reactions around earnings and event announcements.

Recent Company History

Over the past few months, ETON has mixed operational updates with investor outreach. A Feb 2, 2026 licensing deal for an ultra-rare disease candidate under FDA review saw shares move +1.07%. Multiple conference participation announcements in Nov 2025 produced modest positive and negative moves. The Q3 2025 earnings release highlighted product sales of $22.5M and strong growth but coincided with a slight -0.57% reaction. Today’s Leerink conference participation continues this pattern of ongoing investor engagement updates.

Market Pulse Summary

This announcement highlights ETON’s continued engagement with institutional investors through one-on...

Analysis

This announcement highlights ETON’s continued engagement with institutional investors through one-on-one meetings at a major healthcare conference on March 11, 2026. In recent months, the company combined conference participation with licensing activity and strong Q3 2025 financial growth. Investors may watch how this outreach supports interest in its rare disease portfolio, upcoming regulatory milestones, and future earnings reports, given the stock’s position below its 52-week high yet above prior lows.

AI-generated analysis. Not financial advice.

DEER PARK, Ill., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that members of the Company’s executive leadership team will host one-on-one meetings at the Leerink Partners Global Healthcare Conference on Wednesday, March 11, 2026 in Miami, Florida.

To schedule a 1x1 meeting with the Company, please contact your Leerink Partners institutional sales representative.

About Eton Pharmaceuticals
Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently has eight commercial rare disease products: KHINDIVI™, INCRELEX^®, ALKINDI SPRINKLE^®, GALZIN^®, PKU GOLIKE^®, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has four additional product candidates in late-stage development: Amglidia^®, ET-700, ET-800 and ZENEO^® hydrocortisone autoinjector. For more information, please visit our website at www.etonpharma.com.

Investor Relations:
Lisa M. Wilson, In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com

Source: Eton Pharmaceuticals.

FAQ

When will Eton Pharmaceuticals (ETON) meet investors at the Leerink Partners Global Healthcare Conference?

Eton will hold one-on-one meetings on Wednesday, March 11, 2026 in Miami. According to Eton, executive leadership will host 1x1 investor meetings at the Leerink Partners Global Healthcare Conference and meetings must be scheduled via Leerink institutional sales representatives.

How can investors schedule a 1x1 meeting with Eton Pharmaceuticals (ETON) for March 11, 2026?

Investors should contact their Leerink Partners institutional sales representative to schedule a meeting. According to Eton, all one-on-one meeting arrangements are handled through Leerink Partners' institutional sales team rather than directly through the company.

Who from Eton Pharmaceuticals (ETON) will attend the March 11, 2026 Leerink conference?

Members of Eton's executive leadership team will host the one-on-one meetings. According to Eton, executive leadership will represent the company in individual investor meetings at the Leerink Partners Global Healthcare Conference in Miami.

Where and what is the purpose of Eton Pharmaceuticals' (ETON) participation on March 11, 2026?

Eton will participate in one-on-one investor meetings at the Leerink Partners Global Healthcare Conference in Miami. According to Eton, the meetings provide institutional investors opportunities to discuss the company's strategy and developments with executive leadership.